Drug intelligence / Profile preview

NBI-921355

Development stage: Phase 1
Lead developer: Neurocrine Biosciences
Modality: Small Molecules
Administration: Oral

Overview

NBI-921355 is an investigational small molecule drug that acts as a selective inhibitor of voltage-gated sodium channels Nav1.2 and Nav1.6. It is being developed for the potential treatment of certain types of epilepsy, with its primary mechanism aimed at stabilizing hyperexcitable neuronal membranes to prevent seizures. The drug was originally discovered by Xenon Pharmaceuticals and is being co-developed with Neurocrine Biosciences[1][4][5]. As of early 2025, it remains in Phase 1 clinical trials for epilepsy[1][7].

Targets

SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on NBI-921355.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBI-921355.